Science & Enterprise subscription

Follow us on Twitter

  • It's the data, and they ain't stupid ... Big Tech and antitrust: Pay attention to the math behind the curtain… https://t.co/wPtdsNAX41
    about 2 days ago
  • NEJM Blog ... Home Covid-19 testing needed now ... https://t.co/wgteBZUUa4
    about 2 days ago
  • A recent journal article estimates the public investments needed to prevent the next damaging pandemic, against the… https://t.co/CgyvYTtvUW
    about 2 days ago
  • New post on Science and Enterprise: Infographic – An Ounce of Pandemic Prevention https://t.co/6soeKJbv8t #Science #Business
    about 2 days ago
  • Sponsored post on Science and Enterprise: Take care of your liver !!! … Stay healthy https://t.co/yPx9Bm6qvi
    about 2 days ago

Please share Science & Enterprise

European Approval Granted for Temporary Heart Pump

Human heart and arteries (Yale School of Medicine/Wikimedia Commons)

(Yale School of Medicine/Wikimedia Commons)

Abiomed Inc. in Danvers, Massachusetts, a developer of medical devices for circulatory support, says its Impella cVAD heart pump has received a CE mark indicating approval to market the device in EU member countries. The marking, an  acronym for the French Conformité Européenne, certifies that a product has met EU health, safety, and environmental requirements.

The company says the Impella cVAD is a minimally invasive, catheter-based pump that is inserted under the skin, without the need for surgical intervention, and designed to provide temporary circulatory support with a peak flow of about 4 liters of blood per minute. The devise is intended for use in cardiology and cardiac surgery for up to 5 days.

Abiomed says the CE mark permits use of the Impella cVAD for patients with reduced left ventricular function, such as post-cardiotomy, low output syndrome, cardiogenic shock after acute myocardial infarction, or for myocardial protection after acute myocardial infarction. The Impella cVAD may also be used as a cardiovascular support system during coronary bypass surgery on the beating heart.

The company expects the Impella cVAD to be fully available in Europe by the summer of 2012. The device is not yet approved for sale or use in the U.S.

Read more:

*     *     *

Comments are closed.